NSC antagonists are disclosed as useful in the treatment of dementia in delaying the onset of dementia and in the prevention of dementia. Dementia so treated may be for example Alzheimer's Disease (AD). NSC antagonists for treating dementia such as AD may be administered alone a) in combination with other drugs used for treating dementia b) in combination with drugs that stabilize or increase blood plasma glucose levels or with both a) and b). Pharmaceutical compositions dosage forms and methods...

The invention provides liquid formulations of compounds that act at sulfonylurea receptors that are suitable for intravenous and intra-arterial infusion. Compounds active at a sulfonylurea receptor include glibenclamide tolbutamide repaglinide nateglinide meglitinide midaglizole LY397364 LY389382 glyclazide and glimepiride. Liquid formulations may be concentrated solutions suitable for storage; may be diluted (e.g. dilution of 1 : 1 or 1 : 1.2) suitable for bolus injections and may be further di...